Qlt Inc (QLT.TO) 6.52 $QLT.TO
QLT Announces Publication in The Lancet of Phase 1b Data for QLT091001 in Leber Congenital Amaurosis Due to LRAT or RPE65 Mutations
GlobeNewswire - Mon Jul 14, 6:00AM CDT
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company"

today announced the publication of data from its Phase 1b proof-of-concept trial of QLT091001 in subjects with Leber Congenital Amaurosis (LCA) due to inherited genetic mutations in retinal pigment epithelium (RPE65) or lecithin:retinol acyltransferase (LRAT) in The Lancet. The peer-reviewed journal article is available first in the online edition of The Lancet at www.thelancet.com. In the study, treatment for 7 days with oral QLT091001 demonstrated a restoration of clinically meaningful visual function in 11 of the 14 LCA patients, as measured by improvement in Goldmann Visual Fields (GVF) or visual acuity. Self-reported or parent-reported improvements in activities of daily living supported these findings.
Netflix and Twitter are big market movers
AP - Tue Jul 01, 3:22PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Tuesday on the New York Stock Exchange and the Nasdaq Stock Market:
Nasdaq stocks posting largest percentage increases
AP - Thu Jun 26, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Auxilium Pharmaceuticals to Merge with Canadian Biotechnology Company QLT
CNW Group - Thu Jun 26, 3:19PM CDT
Accelerates Auxilium's Ongoing Transformation Into Leading North American Specialty Biopharmaceutical Company
Auxilium to combine with eye drug maker QLT
AP - Thu Jun 26, 12:47PM CDT
NEW YORK (AP) — Auxilium Pharmaceuticals Inc. said Thursday that it plans to combine with Canadian eye drug maker QLT Inc. in an all-stock deal worth about $345 million.
QLT Announces Fourth Quarter and Year End 2013 Results
GlobeNewswire - Fri Feb 28, 6:00AM CST
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company"

is a biotechnology company dedicated to the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. The Company reported financial results today for the fourth quarter and year ended December 31, 2013. Unless otherwise specified, all amounts are reported in U.S. dollars and in accordance with U.S. GAAP.
QLT Announces Positive Preliminary Results From Phase 1b Retreatment Trial of QLT091001 in Subjects With Leber Congenital Amaurosis and Retinitis Pigmentosa Due to Mutations in LRAT or RPE65
GlobeNewswire - Thu Feb 27, 6:45AM CST
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company"

today announced positive preliminary results from its international, multi-center, Phase 1b clinical trial of repeated treatments of oral QLT091001 in subjects with Leber Congenital Amaurosis (LCA) or Retinitis Pigmentosa (RP) due to inherited genetic mutations in retinal pigment epithelium (RPE65) or lecithin:retinol acyltransferase (LRAT).
QLT Announces Second Quarter 2013 Results
GlobeNewswire - Thu Aug 01, 6:31AM CDT
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company"

is a biotechnology company dedicated to the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. The Company today reported financial results for the second quarter ended June 30, 2013. Unless specified otherwise, all amounts are in U.S. dollars and in accordance with U.S. GAAP.
QLT Announces Completion of US$200 Million Special Cash Distribution to Shareholders
GlobeNewswire - Thu Jun 27, 4:30PM CDT
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company"

is pleased to announce that the Company has completed today the previously announced special cash distribution (the "Cash Distribution"

in the amount of US$200 million, by way of a reduction of the capital of the Company's common shares (the "Shares"

. As a result, QLT's shareholders as of June 24, 2013, the record date for the distribution (the "Record Date"

, received a special cash distribution payment of US$3.915283 per Share (the "Distribution Payment"

. The Distribution Payment per Share was determined based on the number of issued and outstanding Shares of the Company as of the Record Date. As previously announced, the Distribution Payments to shareholders were made without Canadian withholding taxes of up to 25% being payable, pursuant to an Advance Tax Ruling received from Canadian tax authorities.
QLT Announces Shareholder Approval of US$200 Million Special Cash Distribution to Shareholders and Election Results
GlobeNewswire - Fri Jun 14, 3:25PM CDT
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company"

is pleased to announce that at the annual general and special meeting (the "Meeting"

held today, QLT's shareholders approved a special cash distribution in the amount of US$200 million, by way of a reduction of the capital of the Company's common shares (the "Shares"

. As a result, QLT's shareholders as of June 24, 2013, the record date for the distribution (the "Record Date"

, will receive a special cash distribution payment of approximately US$3.92 per Share (the "Distribution Payment"

based upon the current number of issued and outstanding Shares of the Company. The final amount of the Distribution Payment per Share will be determined based upon the number of issued and outstanding Shares on the Record Date, and will be payable on June 27, 2013. As previously announced, the Company will be able to make the Distribution Payment to shareholders without Canadian withholding taxes of up to 25% being payable, pursuant to an Advance Tax Ruling received from Canadian tax authorities.
QLT Announces First Quarter 2013 Results
GlobeNewswire - Thu May 02, 6:30AM CDT
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company"

is a biotechnology company dedicated to the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. The Company today reported financial results for the first quarter ended March 31, 2013. Unless specified otherwise, all amounts are in U.S. dollars and in accordance with U.S. GAAP.
QLT plans $200M tax-free cash distribution
AP - Mon Apr 15, 10:46AM CDT
NEW YORK (AP) — Canadian drug maker QLT Inc. said Monday it plans to distribute $200 million in cash to its shareholders.
QLT Proposes US$200 Million Special Cash Distribution to Shareholders
GlobeNewswire - Mon Apr 15, 6:30AM CDT
-- Cash Distribution Free of Canadian Withholding Taxes
QLT Completes Sale of Punctal Plug Technology to Mati Therapeutics
GlobeNewswire - Thu Apr 04, 3:06PM CDT
QLT Inc. (Nasdaq:QLTI) (TSX:QLT) ("QLT" or the "Company"

announced today that it has completed the sale of the Company's punctal plug drug delivery system ("PPDS"

technology (the "Technology"

to Mati Therapeutics Inc. ("Mati"

, a development company founded by Robert Butchofsky, QLT's former President & CEO. As previously reported, on December 24, 2012, the Company entered into an exclusive option agreement with Mati under which QLT granted Mati a 90-day option to acquire assets related to QLT's PPDS Technology in exchange for $500,000. On April 3, 2013, following Mati's exercise of the option, the Company and Mati entered into an asset purchase agreement and completed the sale of the PPDS Technology to Mati. Under the terms of the asset purchase agreement, QLT received an additional payment of $750,000 at closing and is eligible to receive potential payments upon the satisfaction of certain product development and commercialization milestones that could reach $19.5 million (or exceed that amount if more